Antagonism of morphine-induced catalepsy by L-prolyl-L-leucyl-glycinamide.
In view of the recently demonstrated extra-endocrine central actions of hypothalamic releasing hormones, we have investigated the effects of prolyl-leucyl-glycinamide (PLG) and thyrotropin releasing hormone (TRH) on morphine-induced catalepsy. Although acute administration of PLG (10 mg kg-1 s.c.) slightly attenuated the cataleptic response, chronic PLG treatment (10 mg kg-1 s.c. for 10 days) virtually abolished morphine-induced catalepsy. TRH, administered subcutaneously, exhibited little or no anti-cataleptic activity. These results are discussed in relation to the possible central site of narcotic-induced catalepsy and the therapeutic potential of PLG in Parkinson's disease.
D000818:Animals; D002375:Catalepsy / Q000139:chemically induced*; D006801:Humans; D009075:MSH Release-Inhibiting Hormone / Q000494:pharmacology*; D008297:Male; D009020:Morphine / Q000037:antagonists & inhibitors*; D010300:Parkinson Disease / Q000188:drug therapy; D051381:Rats; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology
D013973:Thyrotropin-Releasing Hormone; D009020:Morphine; D009075:MSH Release-Inhibiting Hormone